Vilazodone combines the effects of
a selective serotonin reuptake
inhibitor with the 5-HT1A receptor partial agonist activity.
Here, we report the development of a viable and scalable process for
manufacturing vilazodone that features a convergent synthetic approach,
with low cost and high purity. The key indole synthesis was improved
to first make up the hydrazone intermediate and then modify a pendant
hydroxy group to realize a much increased overall yield. This process
was successfully used to prepare >2 kg of vilazodone hydrochloride
with a total yield of 56.2% and purity of 99.93%.